Mirikizumab Shows Promise for Moderate to Severe Crohn's

Already approved for ulcerative colitis, the monoclonal antibody mirikizumab met study endpoints for Crohn's disease response and remission.

Related Keywords

Washington ,District Of Columbia ,United States ,New York ,Brucee Sands ,Eli Lilly ,Icahn School Of Medicine At Mount Sinai ,Langone Health ,Inflammatory Bowel Disease Center ,Icahn School ,Mount Sinai ,Digestive Disease Week ,Simple Endoscopic Score ,Disease Activity Index ,Jordan Axelrad ,